Targeting Fatty Acid Synthase in HER2-Positive Breast Cancer
Author Information
Author(s): Jin Quanri, Yuan Linda X, Boulbes Delphine, Baek Jong Min, Wang Ying Nai, Gomez-Cabello Daniel, Hawke David H, Yeung Sai Ching, Lee Mong Hong, Hortobagyi Gabriel N, Hung Mien Chie, Esteva Francisco J
Primary Institution: The University of Texas M. D. Anderson Cancer Center
Hypothesis
FASN is directly phosphorylated by HER2, resulting in enhanced signaling and tumor progression in breast cancer cells.
Conclusion
FASN phosphorylation by HER2 plays an important role in breast cancer progression and may be a novel therapeutic target in HER2-overexpressing breast cancer cells.
Supporting Evidence
- FASN is phosphorylated when it is in complex with HER2.
- Heregulin-induced FASN phosphorylation resulted in increased FASN enzymatic activity.
- Blocking FASN phosphorylation and activity suppressed the activity of matrix metallopeptidase 9.
- Lapatinib inhibited both basal and heregulin-induced FASN activity.
- C75 suppressed FASN activity by directly inhibiting HER2 and FASN phosphorylation.
- FASN overexpression has been associated with poor prognosis in breast cancer patients.
- Targeting FASN inhibits HER2-overexpressing breast cancer cell invasion.
- FASN phosphorylation plays a critical role in maintaining FASN activity in breast cancer cells.
Takeaway
This study found that a protein called FASN, which helps cancer cells grow, is activated by another protein called HER2. Blocking this interaction could help treat breast cancer.
Methodology
Mass spectrometry, immunofluorescence, immunoprecipitation, Western blotting, kinase assay, FASN enzymatic activity assay, invasion assay, cell viability assay, and zymography were used to study FASN phosphorylation and its effects.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website